Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877292 · ClinicalTrials.gov registry record
A New Prenatal Blood Test for Down Syndrome
A clinical trial, sponsored by Women and Infants Hospital of Rhode Island.
- Completed
- Registry status
- 4,664
- Enrollment target
NCT00877292: Completed study, sponsored by Women and Infants Hospital of Rhode Island.
NCT00877292 is a clinical trial that has completed, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 4,664 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00877292 has completed, sponsored by Women and Infants Hospital of Rhode Island.
- COMPLETED
- Registry status
- 4,664 participants
- Enrollment target
Study Summary
The study will examine the sensitivity and specificity of a circulating cell-free nucleic acid test (DNA/RNA) to identify Down syndrome between about 10 weeks and 21 weeks 6 days gestation. In addition, the new test may be used to identify trisomy 13 and 18 as part of a more complete laboratory developed test. We hypothesize that the new circulating cell-free fetal NA-based test will accurately and precisely measure specific fetal markers in maternal circulation and that measurement will lead to the ability to noninvasively identify with high sensitivity and specificity, fetal chromosome abnormalities, such as Down syndrome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,664 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-05 |
What the finished NCT00877292 record still lists
NCT00877292 is an observational study that tracks outcomes without assigning an intervention. Its 4,664 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00877292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00877292 about?
NCT00877292 is a clinical study titled "A New Prenatal Blood Test for Down Syndrome". The study will examine the sensitivity and specificity of a circulating cell-free nucleic acid test (DNA/RNA) to identify Down syndrome between about 10 weeks and 21 weeks 6 days gestation. In addition, the new test may be used to identify trisomy 13 and 18 as part of a more complete laboratory deve...
What is the current status of trial NCT00877292?
This trial is currently completed. The enrollment target is 4,664 participants. The study started on 2009-02. Estimated completion is 2011-05.
Who is sponsoring clinical trial NCT00877292?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06535139 · 4,630 participants · NA
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
- NCT05486572 · 4,700 participants · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- NCT06888388 · 4,700 participants
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia